SCHEMBL23885530

SCHEMBL23885530

N#Cc1c(N)[nH]c2cc(Br)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP20 Q9Y2K6 1/20 0.51
PLA2G1B P04054 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
PRKACA P17612 1/20 0.44
PRKACG P22612 1/20 0.44
PRKACB P22694 1/20 0.44
PDPK1 O15530 2/20 0.43
JAK2 O60674 2/20 0.43
NSD2 O96028 1/20 0.42
AS3MT Q9HBK9 1/20 0.42
PFKFB1 P16118 1/20 0.38
MAP2K2 P36507 2/20 0.37
MAP2K1 Q02750 2/20 0.37
METAP2 P50579 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PFKFB2 O60825 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30053023 1.00 USP20 (0.51) USP20PLA2G1BATG4BPRKACAPRKACG
SCHEMBL23885655 0.86 PLA2G1B (0.57) USP20PLA2G1BATG4BPRKACAPRKACG
SCHEMBL22122287 0.81 METAP2 (0.38) PRKACAPDPK1JAK2MAP2K2METAP2
SCHEMBL23885618 0.79 USP20 (0.51) USP20PLA2G1BATG4BPRKACAPRKACG
SCHEMBL28385395 0.79 USP20 (0.51) USP20PLA2G1BATG4BPRKACAPRKACG
SCHEMBL23885700 0.79 USP20 (0.66) USP20PLA2G1BATG4BPRKACAPRKACG
SCHEMBL28385691 0.79 USP20 (0.51) USP20PLA2G1BATG4BPRKACAPRKACG
SCHEMBL22152175 0.76 CHRNB2 (0.45) PDPK1JAK2METAP2MEN1KMT2A
SCHEMBL23885417 0.76 NSD2 (0.48) USP20PLA2G1BATG4BPRKACAPRKACG
SCHEMBL23885743 0.76 KIF11 (0.55) USP20PLA2G1BATG4BPRKACAPRKACG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed
EP-4125914-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2023-02-08 EP disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 CN disclosed
WO-2021202977-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP USP20 3411/4885PLA2G1B 717/4885ATG4B 3583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.